<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315246</url>
  </required_header>
  <id_info>
    <org_study_id>302</org_study_id>
    <nct_id>NCT04315246</nct_id>
  </id_info>
  <brief_title>177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors</brief_title>
  <official_title>A Phase I/II Trial of Intracerebroventricular 177Lu DTPA Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Y-mAbs Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Y-mAbs Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adults with leptomeningeal metastasis from solid tumors will be treated with&#xD;
      177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody&#xD;
      targeting B7-H3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 is a dose-escalation phase with a 3+3 sequential-group design in which patients will&#xD;
      receive a dosimetry dose followed by maximum of five 5-week cycles of treatment doses of&#xD;
      intracerebroventricular 177Lu-DTPA-omburtamab.&#xD;
&#xD;
      Part 2 is a cohort-expansion phase in which patients will receive a treatment at the&#xD;
      recommended dose determined in Part 1, until confirmed LM progression, unacceptable toxicity,&#xD;
      or for maximum of 5 cycles, whichever comes first; however, the total number of cycles will&#xD;
      be determined based upon data from Part 1 (e.g., the dosimetry data) to minimize the risk of&#xD;
      radiation necrosis and decreased neurological function End of treatment will take place&#xD;
      within 5 weeks after the last cycle and thereafter the patients will be enter the follow-up&#xD;
      period. The patients will be followed for up until one year after first dose (Part 1) and 2&#xD;
      years after first dose (Part 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will receive up to five cycles of intracerebroventricular 177Lu-DTPA-omburtamab. Safety and efficacy will be investigated during treatment and follow-up period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>1 year</time_frame>
    <description>Safety will be evaluated by the incidence of AEs and SAEs graded according to CTCAE version 5.0. The maximum tolerated dose and the recommended phase 2 dose (RP2D) will be determined in Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs and SAEs</measure>
    <time_frame>2 years</time_frame>
    <description>In Part 2, safety will be evaluated by the incidence of AEs and SAEs graded according to CTCAE version 5.0, at the RP2D defined in Part 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum radioactivity count of lutetium-177 in blood</measure>
    <time_frame>2 weeks</time_frame>
    <description>The time for maximum absorbed radiation dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life of lutetium-177 radioactivity in blood</measure>
    <time_frame>2 weeks</time_frame>
    <description>The time for eliminating half of the radioactivity in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorbed radiation dose of lutetium-177 in blood and cerebrospinal fluid (CSF)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Time-activity curves of radioactivity measurements in blood and CSF will be modeled to deliver absorbed doses in blood and CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry analysis of lutetium-177</measure>
    <time_frame>2 weeks</time_frame>
    <description>Whole-body dosimetry by gamma camera scans and single-photon emission computed tomography (SPECT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax] in CSF</measure>
    <time_frame>7 weeks</time_frame>
    <description>Concentration of 177Lu-DTPA-omburtamab in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax] in serum</measure>
    <time_frame>7 weeks</time_frame>
    <description>Concentration of 177Lu-DTPA-omburtamab in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Life in CSF</measure>
    <time_frame>7 weeks</time_frame>
    <description>Concentration of 177Lu-DTPA-omburtamab in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Life in serum</measure>
    <time_frame>7 weeks</time_frame>
    <description>Concentration of 177Lu-DTPA-omburtamab in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>2 years</time_frame>
    <description>Objective response rate (ORR) will be defined as the proportion of all evaluable patients achieving a response as the best overall response at the time of assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed Duration of Response (DoR)</measure>
    <time_frame>2 years</time_frame>
    <description>DoR is defined as the time from first response to LM progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>PFS is defined as the time from first treatment to date of LM progression or death from any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>OS is defined as the time from first treatment to date of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Leptomeningeal Metastasis</condition>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>177Lu-DTPA-omburtamab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to five cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>radiolabeled DPTA-omburtamab</intervention_name>
    <description>Biological, radiolabeled DPTA-omburtamab</description>
    <arm_group_label>177Lu-DTPA-omburtamab</arm_group_label>
    <other_name>Drug: 177Lu-DTPA-omburtamab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary ductal or lobular breast cancer, non-small cell lung cancer, or malignant&#xD;
             melanoma&#xD;
&#xD;
          -  Type I or Type II LM with a &quot;confirmed&quot; or &quot;probable&quot; diagnosis according to EANO-ESMO&#xD;
             guidelines 2017&#xD;
&#xD;
          -  Life expectancy more than 2 months, as judged by the Investigator&#xD;
&#xD;
          -  ECOG Performance status 0, 1, or 2&#xD;
&#xD;
          -  Acceptable hematological status and liver and kidney function&#xD;
&#xD;
          -  Written informed consent obtained in accordance with local regulations&#xD;
&#xD;
          -  Presence of an intracerebroventricular access device before first dosing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Obstructive or symptomatic communicating hydrocephalus&#xD;
&#xD;
          -  Progressive systemic (extra-leptomeningeal) disease&#xD;
&#xD;
          -  Uncontrolled life-threatening infection&#xD;
&#xD;
          -  Ventriculo-peritoneal shunts without programmable valves. Ventriculo-atrial or&#xD;
             ventriculo-pleural shunts&#xD;
&#xD;
          -  Received craniospinal irradiation (for intraparenchymal or dural metastases) or&#xD;
             intrathecal cytotoxic anti-cancer therapy less than 3 weeks prior to first dose of&#xD;
             177Lu-DTPA-omburtamab&#xD;
&#xD;
          -  Severe non-hematologic organ toxicity; specifically, any renal, cardiac, hepatic,&#xD;
             pulmonary, or gastrointestinal system toxicity Grade 3 or above prior to enrolment&#xD;
&#xD;
          -  Grade 4 nervous system disorder. Hearing loss or stable neurological deficits due to&#xD;
             brain tumor are allowed&#xD;
&#xD;
          -  Unacceptable coagulation function prior to first dosing defined as INR Grade 2 or&#xD;
             above&#xD;
&#xD;
          -  Female of childbearing potential, who are pregnant, breast-feeding, intend to become&#xD;
             pregnant, or are not using highly effective contraceptive methods or male who is not&#xD;
             using highly effective contraceptive method&#xD;
&#xD;
          -  Other significant disease or condition that in the investigator's opinion would&#xD;
             exclude the patient from the trial.&#xD;
&#xD;
          -  Smallest diameter of treated or untreated nodular or linear leptomeningeal metastasis&#xD;
             &gt;0.5 cm on MRI (Part 2 only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joris Wilms</last_name>
    <phone>+4570261414</phone>
    <email>clinicaltrials@ymabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

